Raras
Buscar doenças, sintomas, genes...
Defeito de biossíntese de ácido lipoico
ORPHA:401854DOENÇA RARA

É uma doença metabólica genética que ocorre devido a uma falha no processo de produção de lipoato.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

É uma doença metabólica genética que ocorre devido a uma falha no processo de produção de lipoato.

Publicações científicas
48 artigos
Último publicado: 2025 Nov
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
65 sintomas
👁️
Olhos
34 sintomas
💪
Músculos
23 sintomas
📏
Crescimento
12 sintomas
🦴
Ossos e articulações
11 sintomas
❤️
Coração
11 sintomas

+ 158 sintomas em outras categorias

Características mais comuns

Hipoglicemia
Visão ultrabaixa
Discinesia paroxística
Hipernatremia
Lacticacidúria
Morfologia anormal da camada de fibras nervosas da retina
348sintomas
Sem dados (348)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 348 características clínicas mais associadas, ordenadas por frequência.

HipoglicemiaHypoglycemia
Visão ultrabaixaUltra-low vision
Discinesia paroxísticaParoxysmal dyskinesia
HipernatremiaHypernatremia
LacticacidúriaLacticaciduria

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico48PubMed
Últimos 10 anos111publicações
Pico202521 papers
Linha do tempo
2026Hoje · 2026📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

14 genes identificados com associação a esta condição.

Autosomal recessive
GLRX5Glutaredoxin-related protein 5, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Monothiol glutaredoxin involved in mitochondrial iron-sulfur (Fe/S) cluster transfer (PubMed:20364084, PubMed:23615440). Receives 2Fe/2S clusters from scaffold protein ISCU and mediates their transfer to apoproteins, to the 4Fe/FS cluster biosynthesis machinery, or export from mitochondrion (PubMed:20364084, PubMed:23615440, PubMed:24334290). Required for normal regulation of hemoglobin synthesis by the iron-sulfur protein ACO1 (PubMed:20364084)

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (1)
Mitochondrial iron-sulfur cluster biogenesis
MECANISMO DE DOENÇA

Anemia, sideroblastic, 3, pyridoxine-refractory

A form of sideroblastic anemia, a bone marrow disorder defined by the presence of pathologic iron deposits in erythroblast mitochondria. Sideroblastic anemia is characterized by anemia of varying severity, hypochromic peripheral erythrocytes, systemic iron overload secondary to chronic ineffective erythropoiesis, and the presence of bone marrow ringed sideroblasts. Sideroblasts are characterized by iron-loaded mitochondria clustered around the nucleus. SIDBA3 is refractory to treatment with vitamin B6, while iron chelation therapy may result in clinical improvement. SIDBA3 inheritance is autosomal recessive.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
65.0 TPM
Glândula adrenal
55.8 TPM
Músculo esquelético
48.2 TPM
Ovário
43.3 TPM
Rim - Medula
42.5 TPM
OUTRAS DOENÇAS (2)
spasticity-ataxia-gait anomalies syndromesideroblastic anemia 3
HGNC:20134UniProt:Q86SX6
GCSHGlycine cleavage system H protein, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

The glycine cleavage system catalyzes the degradation of glycine. The H protein (GCSH) shuttles the methylamine group of glycine from the P protein (GLDC) to the T protein (GCST). Has a pivotal role in the lipoylation of enzymes involved in cellular energetics such as the mitochondrial dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex (DLAT), and the mitochondrial dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase com

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (2)
Protein lipoylationGlycine degradation
MECANISMO DE DOENÇA

Multiple mitochondrial dysfunctions syndrome 7

An autosomal recessive disorder biochemically characterized by glycine accumulation in body fluids, including the cerebrospinal fluid, with an elevated cerebrospinal fluid/plasma glycine ratio. The broad clinical spectrum ranges from neonatal fatal glycine encephalopathy to an attenuated phenotype of developmental delay, limited verbal communication, behavioral problems, seizures and variable movement problems. Death in infancy or early childhood may occur.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
20.7 TPM
Tireoide
17.5 TPM
Substância negra
16.6 TPM
Cérebro - Amígdala
13.1 TPM
Hipotálamo
12.9 TPM
OUTRAS DOENÇAS (4)
multiple mitochondrial dysfunctions syndrome 7atypical glycine encephalopathyinfantile glycine encephalopathyneonatal glycine encephalopathy
HGNC:4208UniProt:P23434
IBA57Iron-sulfur cluster assembly factor IBA57, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial protein involved in the maturation of mitochondrial [4Fe-4S]-proteins in the late stage of the iron-sulfur cluster assembly pathway (PubMed:22323289, PubMed:23462291). Operates in cooperation with ISCA2 in the maturation of [4Fe-4S] proteins (PubMed:30269484) Involved in the maturation of mitochondrial 2Fe-2S proteins in the late stage of the iron-sulfur cluster assembly pathway

LOCALIZAÇÃO

Mitochondrion

MECANISMO DE DOENÇA

Multiple mitochondrial dysfunctions syndrome 3

A severe disorder of systemic energy metabolism, resulting in weakness, respiratory failure, lack of neurologic development, lactic acidosis, hyperglycinemia and early death. Some patients show failure to thrive, pulmonary hypertension, hypotonia and irritability. Biochemical features include severe combined deficiency of the 2-oxoacid dehydrogenases, defective lipoic acid synthesis and reduction in activity of mitochondrial respiratory chain complexes.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
9.4 TPM
Cérebro - Hemisfério cerebelar
4.7 TPM
Cerebelo
4.4 TPM
Útero
4.3 TPM
Ovário
4.1 TPM
OUTRAS DOENÇAS (2)
multiple mitochondrial dysfunctions syndrome 3hereditary spastic paraplegia 74
HGNC:27302UniProt:Q5T440
FDXRNADPH:adrenodoxin oxidoreductase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Serves as the first electron transfer protein in all the mitochondrial P450 systems including cholesterol side chain cleavage in all steroidogenic tissues, steroid 11-beta hydroxylation in the adrenal cortex, 25-OH-vitamin D3-24 hydroxylation in the kidney, and sterol C-27 hydroxylation in the liver (By similarity). Also acts as a ferredoxin--NADP(+) reductase essential for coenzyme Q biosynthesis: together with FDX2, transfers the electrons required for the hydroxylation reaction performed by C

LOCALIZAÇÃO

MitochondrionMitochondrion inner membrane

VIAS BIOLÓGICAS (4)
Electron transport from NADPH to FerredoxinEndogenous sterolsPregnenolone biosynthesisDefective CYP11A1 causes AICSR
MECANISMO DE DOENÇA

Auditory neuropathy and optic atrophy

An autosomal recessive disease characterized by hearing loss, visual impairment and optic atrophy, with onset in the first or second decades of life. Optic atrophy is caused by degeneration of nerve fibers which arise in the retina and converge to form the optic disk, optic nerve, optic chiasm and optic tracts.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
302.8 TPM
Testículo
77.8 TPM
Baço
43.0 TPM
Linfócitos
37.8 TPM
Ovário
37.6 TPM
OUTRAS DOENÇAS (3)
multiple mitochondrial dysfunctions syndrome 9bauditory neuropathy-optic atrophy syndromeoptic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome
HGNC:3642UniProt:P22570
LIPT1Lipoyl amidotransferase LIPT1, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Lipoyl amidotransferase that catalyzes the transfer of lipoyl moieties from lipoyl-protein H of the glycine cleavage system (lipoyl-GCSH) to E2 subunits of the pyruvate dehydrogenase complex (PDCE2) (PubMed:29987032). Unable to catalyze the transfer of octanoyl from octanoyl-GCSH to PDCE2 (PubMed:29987032). In vitro, it is also able to catalyze the transfer of the lipoyl group from lipoyl-AMP to the specific lysine residue of lipoyl domains of lipoate-dependent enzymes but this reaction may not

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Protein lipoylation
MECANISMO DE DOENÇA

Lipoyltransferase 1 deficiency

An autosomal recessive disorder due to a defect in lipoic acid metabolism, resulting in severe lactic acidosis and metabolic decompensation. Variable clinical manifestations include delayed psychomotor development, severe hypotonia, dystonia, loss of head control, coma, bradycardia, and pulmonary hypertension.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
14.5 TPM
Tireoide
11.8 TPM
Baço
11.8 TPM
Ovário
11.5 TPM
Próstata
10.8 TPM
OUTRAS DOENÇAS (1)
lipoyl transferase 1 deficiency
HGNC:29569UniProt:Q9Y234
CIAO1Probable cytosolic iron-sulfur protein assembly protein CIAO1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Key component of the cytosolic iron-sulfur protein assembly (CIA) complex, a multiprotein complex that mediates the incorporation of iron-sulfur cluster into extramitochondrial Fe/S proteins (PubMed:17937914, PubMed:23891004, PubMed:38950322). As a CIA complex component, interacts specifically with CIAO2A or CIAO2B and MMS19 to assist different branches of iron-sulfur protein assembly, depending of its interactors. The complex CIAO1:CIAO2B:MMS19 binds to and facilitates the assembly of most cyto

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Cytosolic iron-sulfur cluster assembly
MECANISMO DE DOENÇA

Multiple mitochondrial dysfunctions syndrome 10

An autosomal recessive disorder characterized by proximal and axial muscle weakness, fluctuating creatine kinase elevation, and respiratory insufficiency. Additional features include learning difficulties and neurobehavioral comorbidities. Some affected individuals have mild normocytic to macrocytic anemia. Brain imaging shows increased iron deposition in deep brain nuclei in some patients.

OUTRAS DOENÇAS (1)
multiple mitochondrial dysfunctions syndrome 10
HGNC:HGNC:14280UniProt:O76071
LIASLipoyl synthase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the radical-mediated insertion of two sulfur atoms into the C-6 and C-8 positions of the octanoyl moiety bound to the lipoyl domains of lipoate-dependent enzymes, thereby converting the octanoylated domains into lipoylated derivatives

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Protein lipoylation
MECANISMO DE DOENÇA

Hyperglycinemia, lactic acidosis, and seizures

An enzymatic defect resulting in an autosomal recessive disorder of mitochondrial metabolism. It is characterized by early-onset lactic acidosis, severe encephalomyopathy, and a pyruvate oxidation defect. Affected individuals have neonatal-onset epilepsy, poor growth, psychomotor retardation, muscular hypotonia, lactic acidosis, and elevated glycine concentration in plasma and urine.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
7.5 TPM
Linfócitos
5.5 TPM
Ovário
5.2 TPM
Cervix Ectocervix
3.9 TPM
Cervix Endocervix
3.9 TPM
OUTRAS DOENÇAS (1)
lipoic acid synthetase deficiency
HGNC:16429UniProt:O43766
DLDDihydrolipoyl dehydrogenase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Lipoamide dehydrogenase is a component of the glycine cleavage system as well as an E3 component of three alpha-ketoacid dehydrogenase complexes (pyruvate-, alpha-ketoglutarate-, and branched-chain amino acid-dehydrogenase complex) (PubMed:15712224, PubMed:16442803, PubMed:16770810, PubMed:17404228, PubMed:20160912, PubMed:20385101). The 2-oxoglutarate dehydrogenase complex is mainly active in the mitochondrion (PubMed:29211711). A fraction of the 2-oxoglutarate dehydrogenase complex also locali

LOCALIZAÇÃO

Mitochondrion matrixNucleusCell projection, cilium, flagellumCytoplasmic vesicle, secretory vesicle, acrosome

VIAS BIOLÓGICAS (10)
BCKDH synthesizes BCAA-CoA from KIC, KMVA, KIVBranched-chain amino acid catabolismBranched-chain ketoacid dehydrogenase kinase deficiencyH139Hfs13* PPM1K causes a mild variant of MSUDSignaling by Retinoic Acid
MECANISMO DE DOENÇA

Dihydrolipoamide dehydrogenase deficiency

An autosomal recessive metabolic disorder characterized biochemically by a combined deficiency of the branched-chain alpha-keto acid dehydrogenase complex (BCKDC), pyruvate dehydrogenase complex (PDC), and alpha-ketoglutarate dehydrogenase complex (KGDC). Clinically, affected individuals have lactic acidosis and neurologic deterioration due to sensitivity of the central nervous system to defects in oxidative metabolism.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
73.2 TPM
Coração - Ventrículo esquerdo
70.7 TPM
Músculo esquelético
69.5 TPM
Esôfago - Muscular
69.5 TPM
Glândula adrenal
69.1 TPM
OUTRAS DOENÇAS (1)
pyruvate dehydrogenase E3 deficiency
HGNC:2898UniProt:P09622
ISCA1Iron-sulfur cluster assembly 1 homolog, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in the maturation of mitochondrial 4Fe-4S proteins functioning late in the iron-sulfur cluster assembly pathway. Probably involved in the binding of an intermediate of Fe/S cluster assembly

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (2)
Maturation of TCA enzymes and regulation of TCA cycleMitochondrial iron-sulfur cluster biogenesis
MECANISMO DE DOENÇA

Multiple mitochondrial dysfunctions syndrome 5

An autosomal recessive, severe disorder characterized by early onset neurological deterioration, seizures, cerebral and cerebellar leukodystrophy, dysmyelination, cortical migrational abnormalities, lactic acidosis and early demise.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
49.7 TPM
Brain Frontal Cortex BA9
42.2 TPM
Cerebelo
37.8 TPM
Testículo
36.0 TPM
Pituitária
33.6 TPM
OUTRAS DOENÇAS (1)
multiple mitochondrial dysfunctions syndrome 5
HGNC:28660UniProt:Q9BUE6
ISCA2Iron-sulfur cluster assembly 2 homolog, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in the maturation of mitochondrial 4Fe-4S proteins functioning late in the iron-sulfur cluster assembly pathway. May be involved in the binding of an intermediate of Fe/S cluster assembly

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (2)
Maturation of TCA enzymes and regulation of TCA cycleMitochondrial iron-sulfur cluster biogenesis
MECANISMO DE DOENÇA

Multiple mitochondrial dysfunctions syndrome 4

A severe disorder of systemic energy metabolism, resulting in weakness, respiratory failure, lack of neurologic development, lactic acidosis, hyperglycinemia and early death.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
21.5 TPM
Linfócitos
20.0 TPM
Glândula adrenal
18.8 TPM
Fibroblastos
18.2 TPM
Testículo
17.7 TPM
OUTRAS DOENÇAS (1)
multiple mitochondrial dysfunctions syndrome 4
HGNC:19857UniProt:Q86U28
BOLA3BolA-like protein 3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Acts as a mitochondrial iron-sulfur (Fe-S) cluster assembly factor that facilitates (Fe-S) cluster insertion into a subset of mitochondrial proteins. Probably acts together with NFU1 (PubMed:27532772)

LOCALIZAÇÃO

Mitochondrion

MECANISMO DE DOENÇA

Multiple mitochondrial dysfunctions syndrome 2 with hyperglycinemia

A severe disorder of systemic energy metabolism, resulting in weakness, respiratory failure, lack of neurologic development, lactic acidosis, hyperglycinemia and early death. Some patients show failure to thrive, pulmonary hypertension, hypotonia and irritability. Biochemical features include severe combined deficiency of the 2-oxoacid dehydrogenases, defective lipoic acid synthesis and reduction in activity of mitochondrial respiratory chain complexes.

OUTRAS DOENÇAS (1)
multiple mitochondrial dysfunctions syndrome 2
HGNC:24415UniProt:Q53S33
PMPCBMitochondrial-processing peptidase subunit betaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic subunit of the essential mitochondrial processing protease (MPP), which cleaves the mitochondrial sequence off newly imported precursors proteins (Probable) (PubMed:29576218). Preferentially, cleaves after an arginine at position P2 (By similarity). Required for PINK1 turnover by coupling PINK1 mitochondrial import and cleavage, which results in subsequent PINK1 proteolysis (PubMed:22354088)

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (2)
Mitochondrial protein importProcessing of SMDT1
MECANISMO DE DOENÇA

Multiple mitochondrial dysfunctions syndrome 6

An autosomal recessive, neurodegenerative disorder characterized by basal ganglia lesions, cerebellar atrophy, and neurologic regression in the first year of life. Common features include truncal hypotonia, lack of independent ambulation, poor speech, intellectual disability, and motor abnormalities, such as ataxia, dystonia, and spasticity.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
85.0 TPM
Ovário
68.1 TPM
Cervix Endocervix
66.3 TPM
Útero
65.9 TPM
Artéria tibial
64.7 TPM
OUTRAS DOENÇAS (1)
multiple mitochondrial dysfunctions syndrome 6
HGNC:9119UniProt:O75439
NFU1NFU1 iron-sulfur cluster scaffold homolog, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Iron-sulfur cluster scaffold protein which can assemble [4Fe-4S] clusters and deliver them to target proteins

LOCALIZAÇÃO

MitochondrionCytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Protein lipoylation
MECANISMO DE DOENÇA

Multiple mitochondrial dysfunctions syndrome 1

A severe disorder of systemic energy metabolism, resulting in weakness, respiratory failure, lack of neurologic development, lactic acidosis, hyperglycinemia and early death. Some patients show failure to thrive, pulmonary hypertension, hypotonia and irritability. Biochemical features include severe combined deficiency of the 2-oxoacid dehydrogenases, defective lipoic acid synthesis and reduction in activity of mitochondrial respiratory chain complexes.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
40.0 TPM
Tecido adiposo
36.7 TPM
Aorta
33.9 TPM
Artéria coronária
33.5 TPM
Músculo esquelético
32.6 TPM
OUTRAS DOENÇAS (2)
multiple mitochondrial dysfunctions syndrome 1spastic paraplegia 93, autosomal recessive
HGNC:16287UniProt:Q9UMS0
MECREnoyl-[acyl-carrier-protein] reductase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the NADPH-dependent reduction of trans-2-enoyl thioesters in mitochondrial fatty acid synthesis (fatty acid synthesis type II). Fatty acid chain elongation in mitochondria uses acyl carrier protein (ACP) as an acyl group carrier, but the enzyme accepts both ACP and CoA thioesters as substrates in vitro. Displays a preference for medium-chain over short- and long-chain substrates (PubMed:12654921, PubMed:18479707, PubMed:27817865). May provide the octanoyl chain used for lipoic acid bio

LOCALIZAÇÃO

MitochondrionCytoplasmNucleus

VIAS BIOLÓGICAS (1)
Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA
MECANISMO DE DOENÇA

Dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalities

An autosomal recessive neurologic disorder characterized by childhood-onset dystonia, basal ganglia degeneration and optic atrophy with decreased visual acuity. Dystonia is defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYTOABG severity is variable, and some patients lose independent ambulation.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
16.3 TPM
Nervo tibial
15.9 TPM
Útero
15.8 TPM
Cervix Endocervix
15.2 TPM
Cervix Ectocervix
14.8 TPM
OUTRAS DOENÇAS (3)
dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalitiesoptic atrophy 16obsolete autosomal recessive optic atrophy
HGNC:19691UniProt:Q9BV79

Variantes genéticas (ClinVar)

211 variantes patogênicas registradas no ClinVar.

🧬 GLRX5: NM_016417.3(GLRX5):c.268G>A (p.Val90Met) ()
🧬 GLRX5: NM_016417.3(GLRX5):c.336del (p.Tyr113fs) ()
🧬 GLRX5: NM_016417.3(GLRX5):c.367G>C (p.Asp123His) ()
🧬 GLRX5: NM_016417.3(GLRX5):c.80C>G (p.Pro27Arg) ()
🧬 GLRX5: GRCh37/hg19 14q31.1-32.2(chr14:79886061-96870809)x1 ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Defeito de biossíntese de ácido lipoico

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
0 papers (10 anos)
#1

Dapagliflozin mitigates myocardial inflammation and metabolic stress in heart failure through STAT1 inhibition: Evidence from multi-omics analyses and experimental exploration.

PloS one2026

Heart failure (HF) is a global health challenge with high morbidity and mortality. While dapagliflozin (DAPA), a sodium-glucose cotransporter 2 inhibitor, has proven clinical benefits in HF, its molecular mechanisms remain unclear. We integrated bulk and single-cell transcriptomic analyses with experimental validation to investigate the role of STAT1 in HF and its modulation by DAPA. Bulk RNA sequencing data from the GSE57345 dataset were analyzed for differential expression, enrichment, and weighted gene co-expression network analysis (WGCNA) to identify hub regulators. Single-cell RNA sequencing data (GSE145154) included normal controls (n = 4), dilated cardiomyopathy (DCM, n = 8), ischemic cardiomyopathy infarct regions (ICM_MI, n = 6), and non-infarct regions (ICM_NMI, n = 6), and were processed with Seurat and Harmony for integration, clustering, myeloid subcluster profiling, and AUCell pathway scoring. For in vivo validation, a rat model of myocardial infarction-induced HF was established and divided into control, HF, and HF+DAPA groups (6 mg/kg/day for 4 weeks). Histological examination, Western blotting, ELISA, flow cytometry, and serum bile acid assays were conducted. For in vitro assays, STAT1-overexpressing H9C2 cardiomyocytes were generated by lentiviral transduction. Cell viability (CCK‑8), STAT1 expression (qPCR and Western blot), and apoptosis (Annexin V/PI flow cytometry) were assessed with or without DAPA treatment. Transcriptomic analyses revealed widespread activation of bile acid, amino acid, and lipoic acid metabolic pathways in HF, coupled with immune remodeling dominated by increased M1 and reduced M2 macrophages. STAT1 emerged as a central hub gene linking metabolic stress and immune imbalance. Single-cell analysis confirmed aberrant STAT1 expression particularly in M1 and proliferating myeloid clusters. In vivo, DAPA suppressed myocardial STAT1 expression, alleviated inflammation, normalized macrophage polarization, and reduced cytokine and bile acid abnormalities. In vitro, DAPA rescued STAT1-overexpressing cardiomyocytes by restoring viability and reducing apoptosis. STAT1 acts as a pivotal mediator bridging metabolic disturbances and immune dysregulation in HF. DAPA alleviates HF by inhibiting STAT1 signaling, thereby restoring immunometabolic balance and protecting cardiac tissue. These findings provide mechanistic insight into the cardioprotective effects of DAPA and position STAT1 as a promising biomarker and potential therapeutic candidate for HF management.

#2

α-Lipoic Acid Alleviates Non-Alcoholic Fatty Liver Disease by Elevating Chaperone-Mediated Autophagy and Increasing β-Oxidation via AMPK-TFEB Axis.

Nutrients2026 Jan 26

Non-alcoholic fatty liver disease (NAFLD) is a prevalent chronic liver disorder associated with impaired lipid metabolism and oxidative stress. As a natural antioxidant and dithiol compound, α-lipoic acid (ALA) may play a beneficial role in modulating hepatic metabolism. This study investigates the potential mechanisms through which ALA may alleviate NAFLD. To construct an NAFLD model, NCTC 1469 cells were exposed to oleic acid and palmitic acid (OA/PA) and glucose for 24 h. RT-qPCR, Western blotting, and siRNA analyses were used to examine the effects and mechanisms of ALA. In vivo, C57BL/6J mice were fed a high-fat diet for 11 weeks and treated with ALA (200 mg/kg/day, intragastrical) for 4 weeks to evaluate its impact on NAFLD. In NCTC 1469 cells exposed to OA/PA and glucose, ALA markedly reduced lipid accumulation by activating TFEB, which in turn promoted fatty acid β-oxidation and chaperone-mediated autophagy (CMA). Furthermore, ALA activated NRF2-dependent CMA and mitigated oxidative stress. Inhibition of AMPK or silencing of TFEB/NRF2 abolished these effects, indicating the key role of the AMPK-TFEB/NRF2 axis. In HFD-fed mice, ALA alleviated hepatic steatosis, serum lipid abnormalities, and liver injury, consistent with its activation of CMA and β-oxidation and reduction in oxidative stress via this pathway. ALA synchronously activates CMA, β-oxidation, and antioxidant responses via a unified AMPK pathway to reduce lipid accumulation and oxidative stress, providing a mechanistically integrated therapeutic strategy for NAFLD.

#3

Metabolic shifts, a consequence of hyperosmolarity, are a hallmark of mental disorders.

Journal of psychiatric research2026 Apr

Mental and neurodevelopmental disorders are heterogeneous, complex, and overlapping entities. Despite progress, their neurobiological underpinnings are not well understood, and current treatments have limited efficacy. However, a growing number of studies have shown impaired brain and systemic energy metabolism evidenced by low-grade inflammation, metabolic syndrome, mitochondrial dysfunction, and abnormal glucose utilization, although their underlying mechanisms remain poorly understood. This paper reviews metabolic shifts in mental disorders, examines the underlying mechanisms driving these metabolic abnormalities in patient subgroups, and explores targeted therapeutic strategies. We argue here that this inflammation results in hyperosmolarity because of increased protein concentration in the extracellular fluid, resulting from vascular leakages. Hyperosmolarity exerts pressure on the capillaries resulting in altered blood flow (hypoperfusion and/or hyper perfusion). Another consequence of hyperosmolarity is metabolic shifts such as aerobic glycolysis. Hyperosmolarity is also responsible for releasing neurotransmitters such as serotonin, dopamine, glutamate, or gamma-aminobutyric acid (GABA). Drugs known to interfere with metabolism such as methylene blue and lipoic acid have been found to have antidepressant, anxiolytic, and neuroprotective effects (both in animals and in humans) in a large array of mental disorders. We suggest that metabolic shifts are a hallmark of mental disorders and that treatments aiming to alleviate these metabolic shifts may improve patients' prognoses. Mechanisms-based treatments should be tested in future clinical trials, where subgroups of patients characterized as having the most profoundly impaired metabolism should be included, following the rules of precision psychiatry.

#4

A single-component photo-crosslinked chitosan hydrogel with inherent antimicrobial and antioxidant capabilities for wound healing.

Journal of materials chemistry. B2026 Feb 11

The development of multifunctional chitosan-based hydrogels for wound healing often relies on complex compositions or external initiators, which can limit their clinical applicability. Herein, we report a novel chitosan-based hydrogel dressing (LQCS) engineered through a facile modification with lipoic acid (LA) and a quaternary ammonium salt (QAS), enabling intrinsic antibacterial and antioxidant activities without complex components. A key innovation of this system is its initiator-free, UV-triggered gelation via disulfide ring-opening polymerization of LA, which facilitates in situ formation and conformal coverage of irregular wounds. The integrated QAS moieties endow the hydrogel with excellent broad-spectrum antimicrobial activity, demonstrating bactericidal rates of 90.1% against Escherichia coli and 92.3% against Staphylococcus aureus. Simultaneously, the LA component confers remarkable antioxidant capacity, effectively scavenging reactive oxygen species (ROS) at the wound site. In a full-thickness skin defect model, the LQCS hydrogel significantly accelerated wound closure by mitigating inflammation and promoting angiogenesis. This study presents a simple yet effective strategy for creating an all-in-one hydrogel dressing, which integrates green fabrication, multi-bioactivity, and pro-healing functions, holding great potential for advanced wound care.

#5

An Injectable and Modular NO-Adaptive Delivery System for Modulating Regenerative Microenvironment in Long-Segment Nerve Injury.

Advanced materials (Deerfield Beach, Fla.)2026 Feb

Repairing long-segment peripheral nerve injuries remains a significant clinical challenge, hindered by oxidative stress, inflammation, insufficient revascularization, and limited axonal regeneration speeds. This study addresses these barriers by reconstructing the nerve regeneration microenvironment, enhancing cell migration, and accelerating axonal growth. An integrated regenerative microenvironment combining chemical signals, micro/nano structures, and electrical stimulation is developed. Specifically, nitric oxide (NO), a versatile signaling molecule, is dynamically released using sustained and responsive-release strategies to regulate oxidative stress and inflammation effectively. Furthermore, a gelatin-lipoic acid-seleno-lipoic acid (Gel-LA-SA) microgel-based hydrogel is designed, forming interconnected macroporous scaffolds that significantly enhance cell infiltration and growth compared to traditional hydrogels. Additionally, a non-invasive electroactive conduit is constructed to provide external electrical stimulation, promoting nerve cell migration and nerve growth factor secretion. Together, these elements guide axonal regeneration, support rapid revascularization, and enhance nutrient supply. By integrating NO signaling, advanced hydrogel scaffolds, and electrical stimulation, this multifunctional conduit effectively addresses the critical barriers to regenerating nerves across extensive defect sites, offering a promising approach for repairing long-segment peripheral nerve injuries and providing insights into broader applications for neurological disease treatment and tissue regeneration.

Publicações recentes

Ver todas no PubMed

📚 EuropePMCmostrando 111

2026

Dapagliflozin mitigates myocardial inflammation and metabolic stress in heart failure through STAT1 inhibition: Evidence from multi-omics analyses and experimental exploration.

PloS one
2026

α-Lipoic Acid Alleviates Non-Alcoholic Fatty Liver Disease by Elevating Chaperone-Mediated Autophagy and Increasing β-Oxidation via AMPK-TFEB Axis.

Nutrients
2026

Metabolic shifts, a consequence of hyperosmolarity, are a hallmark of mental disorders.

Journal of psychiatric research
2026

A single-component photo-crosslinked chitosan hydrogel with inherent antimicrobial and antioxidant capabilities for wound healing.

Journal of materials chemistry. B
2026

An Injectable and Modular NO-Adaptive Delivery System for Modulating Regenerative Microenvironment in Long-Segment Nerve Injury.

Advanced materials (Deerfield Beach, Fla.)
2025

Mitochondria-targeting compounds for management of metabolic and hemostatic abnormalities associated with heart dysfunctions in experimental type 2 diabetes.

Endocrine regulations
2025

Light responsive chitosan hydrogel incorporated with PCN-224@berberine for antibiotic resistant bacterial infected wound management.

International journal of biological macromolecules
2025

ROS/Glucose-Dissociable EGCG-Coated Oxygen-Supplying Nanocomposite Hydrogel for Diabetic Wound Therapy.

International journal of nanomedicine
2025

Alpha-lipoic acid reduces oxidative damage and ameliorates follicular abnormalities in vitrified cat ovarian tissue.

Frontiers in endocrinology
2026

Hydrogen-releasing electroactive nerve guidance conduits promote peripheral nerve regeneration by remodeling the microenvironment.

Biomaterials
2025

Metabolic signatures and a diagnostic model for citrin deficiency based on urinary organic acids.

Clinical and translational medicine
2025

Alpha-lipoic acid supplementation improves pathological alterations in cellular models of Friedreich ataxia.

Orphanet journal of rare diseases
2025

Pyruvate dehydrogenase complex component B: A Gene Associated with Cuproptosis and Encoding the Beta Subunit of Pyruvate Dehydrogenase Is Involved in the Oxidative Decarboxylation Reaction.

DNA and cell biology
2025

Copper metabolism and cuproptosis: broad perspectives in the treatment of hepatocellular carcinoma.

Frontiers in oncology
2025

Role of Morin & Alpha-Lipoic Acid in Diabetic Neuropathic Pain.

Central nervous system agents in medicinal chemistry
2025

Lon1 Protease Controls PentatricoPeptide-Repeat (PPR)-Mediated RNA Processing in Arabidopsis Mitochondria.

Journal of experimental botany
2025

Targeting GPX4-Dependent Ferroptosis via a Dihydroartemisinin-Conjugated Cross-Linked Lipoic Acid Nanodrug for Endometrial Carcinoma Therapy.

Bioconjugate chemistry
2025

ROS/pH Dual-Responsive Hydrogel Dressings Loaded with Amphiphilic Structured Nano Micelles for the Repair of Infected Wounds.

International journal of nanomedicine
2025

Poly(thioctic acid)-based supramolecular hydrogels with UV-triggered on-demand H2S release for burn wound healing.

Journal of controlled release : official journal of the Controlled Release Society
2025

Fruit-specific overexpression of lipoyl synthase increases both bound and unbound lipoic acid and alters the metabolome of tomato fruits.

Frontiers in plant science
2025

Time-resolved mitochondrial screen identifies regulatory components of oxidative metabolism.

EMBO reports
2025

Role of BOLA3 in the mitochondrial Fe-S cluster clarified by metabolomic analysis.

Molecular genetics and metabolism
2025

A narrative literature review about alpha-lipoic acid role in dry eye and ocular surface disease.

Acta ophthalmologica
2025

Management of Oxidative Stress and Inflammation in Patients with Symptomatic Dry Eye Disease Treated with a Preservative-Free Ophthalmic Emulsion Combining Alpha-Lipoic Acid and High Molecular Weight Sodium Hyaluronate.

Advances in therapy
2025

A narrative review on diagnosis and treatment of ifosfamide-induced encephalopathy, the perspective of a EURACAN reference center for sarcomas.

Frontiers in pharmacology
2025

Expanded Clinical Phenotype and the Role of Untargeted Metabolomics Analysis in Confirming the Diagnosis of Sodium-Dependent Multivitamin Transporter Deficiency.

American journal of medical genetics. Part A
2025

Construction of Nanohydroxyapatite/Poly(sodium lipoate)-Based Bioactive Hydrogels for Cranial Bone Regeneration.

Biomacromolecules
2024

Engineered bacterial lipoate protein ligase A (lplA) restores lipoylation in cell models of lipoylation deficiency.

The Journal of biological chemistry
2024

Effects of alpha-lipoic acid and sildenafil citrate on sperm quality in asthenozoospermic men during freezing-thawing processes.

Cryobiology
2024

Defects in the Maturation of Mitochondrial Iron-Sulfur Proteins: Biophysical Investigation of the MMDS3 Causing Gly104Cys Variant of IBA57.

International journal of molecular sciences
2024

A Multi-Target Pharmacological Correction of a Lipoyltransferase LIPT1 Gene Mutation in Patient-Derived Cellular Models.

Antioxidants (Basel, Switzerland)
2024

Exploration of dietary interventions to treat mitochondrial fatty acid disorders in a mouse model.

The Journal of nutritional biochemistry
2024

Ceria Nanoparticle Systems Alleviate Degenerative Changes in Mouse Postovulatory Aging Oocytes by Reducing Oxidative Stress and Improving Mitochondrial Functions.

ACS nano
2024

Persistent Insulin Autoimmune Syndrome in a Caucasian Male in the Absence of Triggers.

Cureus
2024

The emerging importance of the α-keto acid dehydrogenase complexes in serving as intracellular and intercellular signaling platforms for the regulation of metabolism.

Redox biology
2024

Protective effect of alpha‑lipoic acid against in utero cytarabine exposure-induced hepatotoxicity in rat female neonates.

Naunyn-Schmiedeberg's archives of pharmacology
2024

Clinical, biochemical and molecular characterization of a new case with FDX2-related mitochondrial disorder: Potential biomarkers and treatment options.

JIMD reports
2024

Targeting the Metabolic Paradigms in Cancer and Diabetes.

Biomedicines
2024

Novel missense variants cause intermediate phenotypes in the phenotypic spectrum of SLC5A6-related disorders.

Journal of human genetics
2023

Clinical, radiological, biochemical and molecular characterization of a new case with multiple mitochondrial dysfunction syndrome due to IBA57: Lysine and tryptophan metabolites as potential biomarkers.

Molecular genetics and metabolism
2023

Recessive MECR pathogenic variants cause an LHON-like optic neuropathy.

Journal of medical genetics
2023

Aberrant expression of cuproptosis‑related gene LIPT1 is associated with metabolic dysregulation of fatty acid and prognosis in hepatocellular carcinoma.

Journal of cancer research and clinical oncology
2023

Understanding the Molecular Basis of the Multiple Mitochondrial Dysfunctions Syndrome 2: The Disease-Causing His96Arg Mutation of BOLA3.

International journal of molecular sciences
2023

α-Lipoic acid eliminates dioxin-induced offspring sexual immaturity by improving abnormalities in folic acid metabolism.

Biochemical pharmacology
2023

An engineered variant of MECR reductase reveals indispensability of long-chain acyl-ACPs for mitochondrial respiration.

Nature communications
2022

Scavenging ROS and inflammation produced during treatment to enhance the wound repair efficacy of photothermal injectable hydrogel.

Biomaterials advances
2022

Diverse impact of N-acetylcysteine or alpha-lipoic acid supplementation during high-fat diet regime on fatty acid transporters in visceral and subcutaneous adipose tissue.

Advances in medical sciences
2022

Nutraceuticals/Drugs Promoting Mitophagy and Mitochondrial Biogenesis May Combat the Mitochondrial Dysfunction Driving Progression of Dry Age-Related Macular Degeneration.

Nutrients
2022

The Effect of α-Lipoic Acid on Oxidative Stress in Adipose Tissue of Rats with Obesity-Induced Insulin Resistance.

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
2022

Alpha-lipoic acid improved motor function in MPTP-induced Parkinsonian mice by reducing neuroinflammation in the nigral and spinal cord.

Neuroscience letters
2022

Functional characterization of the first lipoyl-relay pathway from a parasitic protozoan.

Molecular microbiology
2022

Mitochondrial iron-sulfur cluster biogenesis and neurological disorders.

Mitochondrion
2021

A Review of Multiple Mitochondrial Dysfunction Syndromes, Syndromes Associated with Defective Fe-S Protein Maturation.

Biomedicines
2021

Modulation of the fecal microbiome and metabolome by resistant dextrin ameliorates hepatic steatosis and mitochondrial abnormalities in mice.

Food & function
2021

Inactivation of genes in oxidative respiration and iron acquisition pathways in pediatric clinical isolates of Small colony variant Enterobacteriaceae.

Scientific reports
2021

Whole exome sequencing identifies a novel homozygous MECR mutation in a Chinese patient with childhood-onset dystonia and basal ganglia abnormalities, without optic atrophy.

Mitochondrion
2021

Alpha-lipoic acid ameliorates cytarabine-induced developmental anomalies in rat fetus.

Human & experimental toxicology
2021

Friedreich Ataxia: current state-of-the-art, and future prospects for mitochondrial-focused therapies.

Translational research : the journal of laboratory and clinical medicine
2020

Alpha-lipoic acid effectively attenuates ionizing radiation-mediated testicular dysfunction in rats: Crosstalk of NF-ĸB, TGF-β, and PPAR-ϒ pathways.

Toxicology
2021

Mitochondrial Fatty Acids and Neurodegenerative Disorders.

The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry
2020

Core-crosslinked nanomicelles based on crosslinkable prodrug and surfactants for reduction responsive delivery of camptothecin and improved anticancer efficacy.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
2019

Mitochondrial lipoylation integrates age-associated decline in brown fat thermogenesis.

Nature metabolism
2020

Impact of sunflower (Helianthus annuus L.) plastidial lipoyl synthases genes expression in glycerolipids composition of transgenic Arabidopsis plants.

Scientific reports
2020

Mitochondrial Fatty Acid Synthase Utilizes Multiple Acyl Carrier Protein Isoforms.

Plant physiology
2020

Metabolic treatments of migraine.

Expert review of neurotherapeutics
2020

Increased antioxidant response in medium-chain acyl-CoA dehydrogenase deficiency: does lipoic acid have a protective role?

Pediatric research
2019

The effects of alpha-lipoic acid supplementation on fasting glucose and lipid profiles among patients with stroke: a systematic review and meta-analysis of randomized controlled trials.

Journal of diabetes and metabolic disorders
2019

Insights on the Use of α-Lipoic Acid for Therapeutic Purposes.

Biomolecules
2019

Staphylococcus aureus Lipoic Acid Synthesis Limits Macrophage Reactive Oxygen and Nitrogen Species Production To Promote Survival during Infection.

Infection and immunity
2019

Unravelling the lipoyl-relay of exogenous lipoate utilization in Bacillus subtilis.

Molecular microbiology
2020

iPSC-derived homogeneous populations of developing schizophrenia cortical interneurons have compromised mitochondrial function.

Molecular psychiatry
2019

Diselenolane-Mediated Cellular Uptake: Efficient Cytosolic Delivery of Probes, Peptides, Proteins, Artificial Metalloenzymes and Protein-Coated Quantum Dots.

Chemistry (Weinheim an der Bergstrasse, Germany)
2019

Alpha lipoic acid protects against dexamethasone-induced metabolic abnormalities via APPL1 and PGC-1 α up regulation.

Steroids
2019

The effect of alpha lipoic acid on uterine wound healing after primary cesarean section: a triple-blind placebo-controlled parallel-group randomized clinical trial.

Archives of gynecology and obstetrics
2018

Evidence that Thiosulfate Inhibits Creatine Kinase Activity in Rat Striatum via Thiol Group Oxidation.

Neurotoxicity research
2018

Nutritional support in mitochondrial diseases: the state of the art.

European review for medical and pharmacological sciences
2018

Protein moonlighting elucidates the essential human pathway catalyzing lipoic acid assembly on its cognate enzymes.

Proceedings of the National Academy of Sciences of the United States of America
2018

Conserved functions of Arabidopsis mitochondrial late-acting maturation factors in the trafficking of iron‑sulfur clusters.

Biochimica et biophysica acta. Molecular cell research
2018

Antioxidants retard the ageing of mouse oocytes.

Molecular medicine reports
2018

ISCA1 mutation in a patient with infantile-onset leukodystrophy causes defects in mitochondrial [4Fe-4S] proteins.

Human molecular genetics
2018

Biochemical Analyses of Human Iron-Sulfur Protein Biogenesis and of Related Diseases.

Methods in enzymology
2018

Impaired endocrine-metabolic homeostasis: underlying mechanism of its induction by unbalanced diet.

Clinical science (London, England : 1979)
2018

Mitochondrial fatty acid biosynthesis and muscle fiber plasticity in very long-chain acyl-CoA dehydrogenase-deficient mice.

FEBS letters
2017

Therapies for mitochondrial diseases and current clinical trials.

Molecular genetics and metabolism
2017

IBA57 mutations abrogate iron-sulfur cluster assembly leading to cavitating leukoencephalopathy.

Neurology. Genetics
2018

Effects of ivermectin and its combination with alpha lipoic acid on expression of IGFBP-3 and HSPA1 genes and male rat fertility.

Andrologia
2017

Control-released Alpha-lipoic acid-loaded PLGA microspheres enhance bone formation in type 2 diabetic rat model.

International journal of clinical and experimental pathology
2017

Impact of mutations within the [Fe-S] cluster or the lipoic acid biosynthesis pathways on mitochondrial protein expression profiles in fibroblasts from patients.

Molecular genetics and metabolism
2017

Biallelic Mutations in LIPT2 Cause a Mitochondrial Lipoylation Defect Associated with Severe Neonatal Encephalopathy.

American journal of human genetics
2017

Mis-targeting of the mitochondrial protein LIPT2 leads to apoptotic cell death.

PloS one
2017

Nitric oxide induces monosaccharide accumulation through enzyme S-nitrosylation.

Plant, cell & environment
2017

α-Lipoic acid treatment prevents cystine urolithiasis in a mouse model of cystinuria.

Nature medicine
2017

α-Lipoic acid potentially targets AMP-activated protein kinase and energy production in the fetal brain to ameliorate dioxin-produced attenuation in fetal steroidogenesis.

The Journal of toxicological sciences
2017

Mitochondrial iron-sulfur cluster biogenesis from molecular understanding to clinical disease.

Neurosciences (Riyadh, Saudi Arabia)
2017

Novel mutations in IBA57 are associated with leukodystrophy and variable clinical phenotypes.

Journal of neurology
2016

α-Lipoic acid attenuates transplacental nicotine-induced germ cell and oxidative DNA damage in adult mice.

Journal of basic and clinical physiology and pharmacology
2016

Differential diagnosis of lipoic acid synthesis defects.

Journal of inherited metabolic disease
2017

Lipoic acid and Calligonum comosumon attenuate aroclor 1260-induced testicular toxicity in adult rats.

Environmental toxicology
2016

Oxidative stress increases the risk of pancreatic β cell damage in chronic renal hypertensive rats.

Physiological reports
2016

Mitochondrial Bol1 and Bol3 function as assembly factors for specific iron-sulfur proteins.

eLife
2016

The Physiological and Molecular Characterization of a Small Colony Variant of Escherichia coli and Its Phenotypic Rescue.

PloS one
2016

Radical S-Adenosylmethionine Enzymes in Human Health and Disease.

Annual review of biochemistry
2016

Roles of Fe-S proteins: from cofactor synthesis to iron homeostasis to protein synthesis.

Current opinion in genetics & development
2016

Mitochondrial Dysfunction in Schizophrenia: Determination of Mitochondrial Respiratory Activity in a Two-Hit Mouse Model.

Journal of molecular neuroscience : MN
2016

Type 1 5'-deiodinase activity is inhibited by oxidative stress and restored by alpha-lipoic acid in HepG2 cells.

Biochemical and biophysical research communications
2016

ZAP1-mediated modulation of triacylglycerol levels in yeast by transcriptional control of mitochondrial fatty acid biosynthesis.

Molecular microbiology
2015

Intra-mitochondrial Methylation Deficiency Due to Mutations in SLC25A26.

American journal of human genetics
2016

Effects of α-lipoic acid therapy on sympathetic heart innervation in patients with previous experience of transient takotsubo cardiomyopathy.

Journal of cardiology
2015

Lipoic acid and pentoxifylline mitigate nandrolone decanoate-induced neurobehavioral perturbations in rats via re-balance of brain neurotransmitters, up-regulation of Nrf2/HO-1 pathway, and down-regulation of TNFR1 expression.

Hormones and behavior
2015

Mitochondrial Pharmaceutics: A New Therapeutic Strategy to Ameliorate Oxidative Stress in Alzheimer's Disease.

Current aging science
2015

Clinical, biochemical, and genetic spectrum of seven patients with NFU1 deficiency.

Frontiers in genetics

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Defeito de biossíntese de ácido lipoico.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Defeito de biossíntese de ácido lipoico

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Dapagliflozin mitigates myocardial inflammation and metabolic stress in heart failure through STAT1 inhibition: Evidence from multi-omics analyses and experimental exploration.
    PloS one· 2026· PMID 41758878mais citado
  2. α-Lipoic Acid Alleviates Non-Alcoholic Fatty Liver Disease by Elevating Chaperone-Mediated Autophagy and Increasing β-Oxidation via AMPK-TFEB Axis.
    Nutrients· 2026· PMID 41683226mais citado
  3. Metabolic shifts, a consequence of hyperosmolarity, are a hallmark of mental disorders.
    Journal of psychiatric research· 2026· PMID 41628532mais citado
  4. A single-component photo-crosslinked chitosan hydrogel with inherent antimicrobial and antioxidant capabilities for wound healing.
    Journal of materials chemistry. B· 2026· PMID 41574936mais citado
  5. An Injectable and Modular NO-Adaptive Delivery System for Modulating Regenerative Microenvironment in Long-Segment Nerve Injury.
    Advanced materials (Deerfield Beach, Fla.)· 2026· PMID 41416362mais citado
  6. A Deep Clinical and Biochemical Characterization of a Patient With Combined Malonic and Methylmalonic Aciduria (CMAMMA).
    JIMD Rep· 2025· PMID 41030468recente
  7. NEDD4L induces mitochondrial dysfunction and neurodegeneration by promoting LIPT2 degradation in Huntington's disease.
    Proc Natl Acad Sci U S A· 2025· PMID 40663606recente
  8. Biallelic Variants in LIPT2 as a Cause of Infantile-Onset Dystonia: Expanding the Clinical and Molecular Spectrum.
    Pediatr Neurol· 2025· PMID 39536593recente
  9. Clinical, biochemical and molecular characterization of a new case with FDX2-related mitochondrial disorder: Potential biomarkers and treatment options.
    JIMD Rep· 2024· PMID 38444577recente
  10. A hub for regulation of mitochondrial metabolism: Fatty acid and lipoic acid biosynthesis.
    IUBMB Life· 2024· PMID 38088214recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:401854(Orphanet)
  2. MONDO:0018424(MONDO)
  3. GARD:12679(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q55788073(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Defeito de biossíntese de ácido lipoico
Compêndio · Raras BR

Defeito de biossíntese de ácido lipoico

ORPHA:401854 · MONDO:0018424
Início
Childhood, Neonatal
MedGen
UMLS
C5680006
Wikidata
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades